KR100661774B1 - 광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도 - Google Patents

광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도 Download PDF

Info

Publication number
KR100661774B1
KR100661774B1 KR1020017002870A KR20017002870A KR100661774B1 KR 100661774 B1 KR100661774 B1 KR 100661774B1 KR 1020017002870 A KR1020017002870 A KR 1020017002870A KR 20017002870 A KR20017002870 A KR 20017002870A KR 100661774 B1 KR100661774 B1 KR 100661774B1
Authority
KR
South Korea
Prior art keywords
pyridyl
piperidinyl
dihydro
methyl
oxadiazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017002870A
Other languages
English (en)
Korean (ko)
Other versions
KR20010073129A (ko
Inventor
안드레아 제드나코비츠
라스즐로 유로그디
라스즐로 데네스
이스트반 쿠르츠
에데 마르반요오스
미할리 바라바스
에르노 박시
즈스즈산나 코롬
졸탄 나기
라스즐로 유르게
제노 스질베레키
카롤리 악사이
피터 크라즈시
지타 스사카이
마그돌나 토로크
Original Assignee
비오렉스 쿠타토 에쉬 훼레스테 에르테
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비오렉스 쿠타토 에쉬 훼레스테 에르테 filed Critical 비오렉스 쿠타토 에쉬 훼레스테 에르테
Publication of KR20010073129A publication Critical patent/KR20010073129A/ko
Application granted granted Critical
Publication of KR100661774B1 publication Critical patent/KR100661774B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020017002870A 1998-12-14 1999-12-07 광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도 Expired - Fee Related KR100661774B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9802897 1998-12-14
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient

Publications (2)

Publication Number Publication Date
KR20010073129A KR20010073129A (ko) 2001-07-31
KR100661774B1 true KR100661774B1 (ko) 2006-12-28

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017002870A Expired - Fee Related KR100661774B1 (ko) 1998-12-14 1999-12-07 광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도

Country Status (27)

Country Link
US (1) US6384029B1 (https=)
EP (1) EP1147105B1 (https=)
JP (2) JP2002532498A (https=)
KR (1) KR100661774B1 (https=)
AT (1) ATE266027T1 (https=)
AU (1) AU765336B2 (https=)
BG (1) BG65179B1 (https=)
BR (1) BR9913982A (https=)
CA (1) CA2340734C (https=)
CZ (1) CZ300764B6 (https=)
DE (1) DE69917074T2 (https=)
DK (1) DK1147105T3 (https=)
EE (1) EE04551B1 (https=)
ES (1) ES2219091T3 (https=)
HR (1) HRP20010133B1 (https=)
HU (1) HU226617B1 (https=)
IL (1) IL141515A (https=)
NO (1) NO317649B1 (https=)
PL (1) PL196584B1 (https=)
PT (1) PT1147105E (https=)
RS (1) RS50129B (https=)
RU (1) RU2222538C2 (https=)
SI (1) SI1147105T1 (https=)
SK (1) SK285582B6 (https=)
UA (1) UA70340C2 (https=)
WO (1) WO2000035914A1 (https=)
ZA (1) ZA200101182B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057664A1 (en) 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
US20110224200A1 (en) 2008-11-18 2011-09-15 Shin-Ichiro Hirai Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde 0-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
MX2019013835A (es) 2017-05-24 2020-07-14 Orphazyme As Inductores de proteinas de choque termico y trastornos frontotemporales.
SG11202011592SA (en) 2018-05-28 2020-12-30 Orphazyme As Hsp70 protein levels in pbmc samples as biomarker for disease
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
EP0858413B1 (en) * 1995-11-03 2003-05-21 Summit Packaging Systems Limited Apparatus for dispensing and filling bags at a checkout counter of a supermarket
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
CZ20011550A3 (cs) 2001-08-15
UA70340C2 (en) 2004-10-15
RS50129B (sr) 2009-03-25
BR9913982A (pt) 2001-06-12
BG105342A (en) 2001-12-29
CA2340734C (en) 2008-10-21
EE200100188A (et) 2002-08-15
JP5620340B2 (ja) 2014-11-05
AU1790600A (en) 2000-07-03
HU226617B1 (en) 2009-04-28
PL196584B1 (pl) 2008-01-31
PT1147105E (pt) 2004-07-30
SK285582B6 (sk) 2007-04-05
ATE266027T1 (de) 2004-05-15
ZA200101182B (en) 2002-02-12
SK2342001A3 (en) 2001-08-06
HRP20010133A2 (en) 2002-02-28
ES2219091T3 (es) 2004-11-16
NO20012310D0 (no) 2001-05-10
DK1147105T3 (da) 2004-06-01
IL141515A0 (en) 2002-03-10
DE69917074D1 (de) 2004-06-09
PL346767A1 (en) 2002-02-25
CA2340734A1 (en) 2000-06-22
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
NO317649B1 (no) 2004-11-29
EP1147105A1 (en) 2001-10-24
HRP20010133B1 (en) 2005-02-28
EP1147105B1 (en) 2004-05-06
JP2011201916A (ja) 2011-10-13
IL141515A (en) 2005-09-25
HUP9802897A2 (hu) 2000-11-28
EE04551B1 (et) 2005-10-17
DE69917074T2 (de) 2005-05-12
US6384029B1 (en) 2002-05-07
BG65179B1 (bg) 2007-05-31
KR20010073129A (ko) 2001-07-31
JP2002532498A (ja) 2002-10-02
CZ300764B6 (cs) 2009-08-05
AU765336B2 (en) 2003-09-18
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
NO20012310L (no) 2001-05-10
YU25001A (sh) 2004-07-15
WO2000035914A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
JP5620340B2 (ja) 光学活性ピリジル−４ｈ−１，２，４−オキサジアジン誘導体およびその血管疾患の治療における使用
JP4316794B2 (ja) イソキノリン誘導体及び医薬
KR890002290B1 (ko) 피페라진 유도체 및 그의 제조방법
JP2011201916A5 (https=)
JPWO1999020620A1 (ja) イソキノリン誘導体及び医薬
JPH05208957A (ja) 新規ｒ−及びｓ−カルバゾール誘導体
US20090253690A1 (en) Pharmaceutically effective compounds
RU2130019C1 (ru) Производные 3(2н)-пиридазинона, фармацевтическая композиция, способ лечения
US4751246A (en) Compositions and method
NO762778L (https=)
JPH05186459A (ja) ２−アミノ−５−シアノ−４−キノリン−１，４−ジヒドロピリジン類
CA2165503A1 (en) 1,4-benzoxazine derivative, pharmaceutical composition containing the same and use thereof
FR2599033A1 (fr) Derives des 3-(hydroxymethyl)-isoquinoleine, procede pour les preparer et compositions pharmaceutiques les contenant
US6071968A (en) Phenylenediamine derivative radical scavenger, brain-infarction depressant, and brain-edema depressant
US4224335A (en) Tetrahydrocarbazoles and their use
KR910004674B1 (ko) 부정맥치료제
FI76319C (fi) Foerfarande foer framstaellning av nya substituerade 3-fenoxi-1-alkoxikarbonyl-alkylamino-propanol-2 -foereningar med -receptor haemmande verkan.
JPH02135A (ja) 多還式化合物とこれを含有する医薬組成物
JP2001114699A (ja) キマーゼ阻害作用を有する化合物を有効成分とする血管新生阻害剤
BE856055A (fr) Derives de 4-hydroxyphenylalcanolamine et leur preparation

Legal Events

Date Code Title Description
R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20101214

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111221

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111221

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000